InvestSMART

Entropy Neurodynamics Limited (ASX:ENP)

ALERT: Price-sensitive ASX Announcement for ENP
Current share price for ENP : $0.037 0.005 (15.63%)+
Announcement
Release
7 Jul 2026 9:37AM
Price at Release
$0.032
Full Release
download
Summary
Entropy Neurodynamics Limited announced groundbreaking results from their Phase 2 trial of TRP-8803, a precision-controlled IV-infused psilocin treatment for binge eating disorder (BED). The trial's Cohort 1 demonstrated 50% clinical remission and 100% clinically meaningful improvement across all treated patients, marking a significant step forward in psychedelic-assisted therapies. These results showed substantial reductions in binge-eating episodes, symptom severity, anxiety, and depression. The clinical trial's success supports the continuation to Cohort 2 and underscores the potential for broader application of this treatment in other neuropsychiatric disorders. The findings position Entropy Neurodynamics at the forefront of developing innovative therapeutics with rapid onset and precise control, highlighting its distinction from traditional oral psychedelic treatments.
Key Points
  • TRP-8803 achieved 50% clinical remission and 100% clinically meaningful improvement in treatment-resistant BED patients.
  • The study demonstrated a 74% reduction in weekly binge-eating episodes, 58% reduction in binge eating severity, 58% reduction in anxiety, and 57% reduction in depression.
  • Precision-controlled IV-infused psilocin offers rapid onset and controlled treatment dynamics compared to oral psilocybin.
  • Clinical results support the progression to a second cohort without protocol modification.
  • Entropy Neurodynamics is positioned as a leader in next-generation psychedelic therapeutics with potential multi-indication expansion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.